Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
|Articles|December 16, 2013
- BioPharm International-12-16-2013
- Volume 2013 eBook
- Issue 1
Leveraging Development Strengths Drives Therapies to Market
Author(s)Cynthia A. Challener
NPS Pharmaceuticals uses its expertise in development, regulatory compliance, and commercialization to bring to market products with orphan drug status.
Advertisement
Established biopharmaceutical company NPS Pharmaceuticals uses its expertise in development, regulatory compliance, and commercialization to bring to market products with orphan drug status.
View other articles in the
Articles in this issue
almost 13 years ago
Creating Better Medicines through Better Conjugationalmost 13 years ago
Recovering Patent Life with Patent Term Extensionalmost 13 years ago
Strategic Outsourcing in Clinical Developmentalmost 13 years ago
Driving Innovation in Biopharmaceuticalsalmost 13 years ago
Crowdfunding Biopharmaceutical Innovationalmost 13 years ago
Restructuring for Biopharmaceutical SuccessAdvertisement
Related to this article
This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Johnson & Johnson's amivantamab (Rybrevant Faspro) won accelerated FDA approval for pretreated recurrent head and neck cancer.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Akeso won NMPA priority review for ivonescimab plus chemotherapy in first-line biliary tract cancer after a phase 3 win over durvalumab plus chemo.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Advertisement
Advertisement
Trending on BioPharm International
1
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
2
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
3
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
4
Ionis Reports 2-Year Donidalorsen (Dawnzera) Data in HAE Prophylaxis
5